DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Several other equities research analysts also recently commented on the stock. Craig Hallum boosted their target price on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Friday, July 18th. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Finally, Lake Street Capital upped their price objective on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, July 18th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, DiaMedica Therapeutics currently has a consensus rating of “Buy” and an average price target of $12.33.

View Our Latest Research Report on DiaMedica Therapeutics

DiaMedica Therapeutics Price Performance

DiaMedica Therapeutics stock opened at $5.30 on Tuesday. The company has a market capitalization of $273.96 million, a PE ratio of -7.68 and a beta of 1.40. DiaMedica Therapeutics has a one year low of $3.19 and a one year high of $6.82. The business has a 50 day simple moving average of $4.76 and a 200 day simple moving average of $4.56.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). Equities analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Jan Stahlberg bought 1,542,857 shares of DiaMedica Therapeutics stock in a transaction dated Wednesday, July 23rd. The shares were bought at an average cost of $3.50 per share, for a total transaction of $5,399,999.50. Following the completion of the transaction, the insider owned 6,764,465 shares of the company’s stock, valued at approximately $23,675,627.50. This trade represents a 29.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey acquired a new position in DiaMedica Therapeutics during the 2nd quarter worth $29,000. Bank of America Corp DE lifted its stake in shares of DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after acquiring an additional 8,274 shares during the period. JPMorgan Chase & Co. bought a new position in DiaMedica Therapeutics in the second quarter valued at about $49,000. Invesco Ltd. acquired a new stake in DiaMedica Therapeutics in the second quarter worth about $54,000. Finally, Intech Investment Management LLC acquired a new stake in DiaMedica Therapeutics in the second quarter worth about $56,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

See Also